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Abstract: A JAK2(V617F) mutation is found in approximately 55% of patients with essential 
thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. 
This hypothesis-generating study (NCT01352585) explored the impact of JAK2(V617F) mutation 
status on treatment response to anagrelide in patients with ET who were intolerant/refractory 
to their current cytoreductive therapy. The primary objective was to compare the proportion of 
JAK2-positive versus JAK2-negative patients who achieved at least a partial platelet response 
(600×109/L) after anagrelide therapy. Of the 47 patients enrolled, 46 were included in the 
full analysis set (JAK2-positive, n=22; JAK2-negative, n=24). At 12 months, 35 patients (n=14 
and n=21, respectively) had a suitable platelet sample; of these, 74.3% (n=26) achieved at 
least a partial response. The response rate was higher in JAK2-positive (85.7%, n=12) versus 
JAK2-negative patients (66.7%, n=14) (odds ratio [OR] 3.00; 95% confidence interval [CI] 
0.44, 33.97). By using the last observation carried forward approach in the sensitivity analysis, 
which considered the imbalance in patients with suitable samples between groups, the over-
all response rate was 71.7% (n=33/46), with 77.3% (n=17/22) of JAK2-positive and 66.7% 
(n=16/24) of JAK2-negative patients achieving at least a partial response (OR 1.70; 95% CI 
0.39, 8.02). There was no significant change in median allele burden over 12 months in the 
12 patients who achieved a response. In conclusion, the overall platelet response rate was high 
in both JAK2-positive and JAK2-negative patients; however, a larger study would be required 
to confirm the differences observed according to JAK2(V617F) mutation status.
Keywords: essential thrombocythemia, mutation, JAK2, anagrelide, treatment response, allele 
burden
Introduction
Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm (MPN) 
characterized by an overproduction of platelets and an increased risk of thrombo-
hemorrhagic complications.1,2 A JAK2(V617F) gain-of-function mutation is found 
in approximately 55% of patients with ET.3–11 JAK2 encodes a cytoplasmic tyrosine 
kinase involved in normal hematopoiesis. Available data show the JAK2 mutation to 
be associated with an increased risk of arterial thrombosis in patients with ET.12,13 The 
risk of evolution to myelofibrosis may also be increased by the JAK2 mutation and 
appears to vary according to allele burden,9,13 although conflicting data are available.4 
In 2008, the World Health Organization (WHO) identified the JAK2 mutation as a 
key diagnostic criterion for Philadelphia-negative MPNs.14 The JAK2 mutation does 
not differentiate between ET and other clonal MPNs (such as polycythemia vera and 
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primary myelofibrosis), but is a molecular marker that distin-
guishes clonal MPNs from reactive thrombocytosis.14,15
Somatic mutations in the thrombopoietin receptor 
(MPL) and calreticulin (CALR) genes have also been 
reported in patients with ET. As with JAK2(V617F), the 
MPL mutation appears to have a phenotype-modifying 
effect in ET; however, this mutation is infrequent, occur-
ring in only around 3% of patients.10,16,17 Most patients with 
ET who do not harbor a JAK2 or MPL alteration carry a 
CALR mutation,18 with an overall CALR mutational fre-
quency in patients with ET up to 32% as reported in one 
recent study.10 The clinical course of ET in patients with 
mutated CALR appears more indolent than that in patients 
with mutated JAK2.19–21
Anagrelide (Xagrid®; 0.5 mg hard capsules, Shire 
Pharmaceutical Contracts Limited, Basingstoke, United 
Kingdom) is an orally active, quinazolone-derived platelet-
lowering agent indicated for second-line treatment of high-
risk patients with ET in Europe.15,22,23 Clinical studies in more 
than 4,000 patients have confirmed the safety and efficacy of 
anagrelide as a platelet-lowering agent in ET.22,24–26
Results from a previous study have suggested that 
anagrelide is similarly effective in controlling platelet levels 
in patients with ET irrespective of JAK2 mutation status.27 
However, JAK2-positive patients have been reported to be 
more sensitive than JAK2-negative patients to hydroxycar-
bamide, as demonstrated by lower platelet counts at lower 
hydroxycarbamide dosages.27 This hypothesis-generating 
study was undertaken to further explore the potential impact 
of JAK2(V617F) mutation status and allele burden on the 
response to anagrelide in patients with ET.
Materials and methods
study design
This was an exploratory, observational, multicenter study 
(clinicaltrials.gov registration: NCT01352585) conducted 
across eleven centers in Italy from July 2011 to September 
2013. Anagrelide 0.5 mg was administered at doses deter-
mined by the treating physician and in accordance with 
the European Union Summary of Product Characteristics 
(SPC).22 Anti-aggregatory therapy was permitted at the dis-
cretion of the investigator. All evaluations were undertaken 
in accordance with routine clinical practice. No visits were 
imposed by the study outside of regularly scheduled visits for 
treatment purposes. Patients who discontinued anagrelide due 
to an adverse drug reaction (ADR) were followed throughout 
the study. All other patients who discontinued were followed 
according to local clinical practice. Patients were withdrawn 
from the study if they switched from anagrelide to another 
ET therapy or combination therapy.
Patients
Patients were eligible for enrollment if they had a con-
firmed diagnosis of ET, according to WHO 2008 diagnostic 
criteria,14 and were intolerant or refractory to their first-line 
or previous cytoreductive therapy due to the lack of efficacy 
or intolerance. Patients had either started anagrelide treat-
ment in the 7 days prior to study entry or a decision had been 
documented to commence anagrelide. Patients were excluded 
from the study if they had a known or suspected intolerance to 
anagrelide or any of the stated ingredients, or closely related 
compounds. Other exclusion criteria were contraindications 
to anagrelide as listed in the anagrelide SPC,22 combination 
therapy with other cytoreductive agents, or participation in 
an interventional research study. Written informed consent 
was obtained from all patients prior to study entry. This 
observational study was conducted in accordance with the 
Declaration of Helsinki, Good Clinical Practice (GCP) stan-
dards, and local ethical and legal requirements.
assessments
Patient data were collected from medical records follow-
ing routine visits at baseline and at 6±2 and 12±3 months 
after the initiation of anagrelide using electronic case report 
forms. As part of routine clinical practice, patients provided 
a 20 mL blood sample for hematological assessment at all 
visits. JAK2 mutation status was measured in all patients 
at baseline. Allele burden was tested at baseline and at 
6 and 12 months in JAK2-positive patients; allele burden 
was measured in both granulocyte DNA and platelet RNA. 
JAK2 mutation status and allele burden were measured at 
a centralized laboratory (University of Florence, Italy) in 
order to standardize the assessments. JAK2 mutation status 
was determined by real-time polymerase chain reaction, and 
JAK2(V617F) allele burden was quantified using the ΔCt 
method as previously described.8,28 The safety of anagrelide 
was assessed by monitoring the incidence and severity of 
ADRs and changes in routine hematology parameters.
statistical analysis
The primary objective of this study was to compare the 
proportion of JAK2-positive versus JAK2-negative patients 
with ET who achieved at least a partial platelet response 
(600×109/L) after anagrelide therapy. Secondary objec-
tives were to compare the proportion of JAK2-positive versus 
JAK2-negative patients with ET who achieved a complete 
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platelet response (400×109/L) after anagrelide therapy, to 
evaluate the relationship between platelet response and allele 
burden in the JAK2-positive group, and to observe the effect 
of anagrelide on routine hematological parameters.
The study was not statistically powered and was explor-
atory in nature. The target sample size was approximately 
60 patients; enrollment was monitored to ensure that a 
minimum of ten patients were recruited into both the JAK2-
positive and JAK2-negative groups. Efficacy was analyzed 
in all patients who received at least one dose of anagrelide 
and had at least one post-baseline platelet count and known 
JAK2 mutation status (full analysis set). Safety was analyzed 
in all enrolled patients who received at least one dose of 
anagrelide (safety set).
For the primary endpoint and other treatment response 
endpoints, the odds ratio (OR) and 95% confidence interval 
(CI) were calculated for the difference in the proportion of 
patients achieving a response between the JAK2-positive and 
JAK2-negative groups. Patients without an available platelet 
sample within the specified time window were excluded from 
the analysis. The efficacy results from the last observation 
carried forward (LOCF) sensitivity analysis are also reported 
here as this approach considers the imbalance in patients 
with suitable platelet samples between the JAK2-positive 
and JAK2-negative groups. For JAK2-positive patients, 
platelet counts were cross-tabulated with the allele burden at 
6 and 12 months; separate summaries were produced for the 
allele burden in granulocyte DNA and platelet RNA. ADRs 
were recorded using the Medical Dictionary for Regulatory 
Activities (MedDRA), version 15.1 or newer.
role of the funding source
The study was funded by Shire Pharmaceutical Development 
Ltd. iMed Comms was funded by Shire for support in writing 
and editing this manuscript.
Results
Patients
Forty-seven patients were enrolled and received at least one 
dose of anagrelide. Of these, 23 (48.9%) were JAK2-positive 
and 24 (51.1%) were JAK2-negative. Forty-six patients 
had at least one post-baseline platelet count and known 
JAK2 status (22 [47.8%] JAK2-positive and 24 [52.2%] 
JAK2-negative) and were included in the analysis of efficacy. 
Fifteen patients in the JAK2-positive group and 21 patients 
in the JAK2-negative group completed the study. The most 
common reason for withdrawal was an adverse event (AE) 
not related to anagrelide (n=6, 12.8%; JAK2-positive, n=4 
[including three due to transformation to myelofibrosis]; 
JAK2-negative, n=2). Three patients (6.4%; JAK2-positive, 
n=2; JAK2-negative, n=1) withdrew from the study due to 
an ADR.
Patient demographics and baseline characteristics were 
generally well balanced between the JAK2-positive and 
JAK2-negative groups (Table 1), except for median (range) 
time since ET diagnosis (8.2 years [0–22] versus 5 years 
[0–16]) and median (range) platelet count (584.0×109/L 
[310–1,158] versus 752.5×109/L [323–2,126]), respectively. 
Mean (standard deviation) age was 58.0 (14.87) years, 
59.6% of patients were female, and most were Caucasian 
(97.9%).
At baseline, most JAK2-positive patients had a low 
(50%) granulocyte DNA and platelet RNA allele burden 
(each n=18 [78.3%]). The distribution of allele burden dif-
fered between granulocyte DNA and platelet RNA. Approxi-
mately half of JAK2-positive patients (n=11 [47.8%]) had a 
granulocyte DNA allele burden of 25% to 50%, with less 
than a third (n=7 [30.4%]) having a granulocyte DNA allele 
burden 25%. In contrast, the majority of JAK2-positive 
patients (n=17 [73.9%]) had a platelet RNA allele burden of 
25% to 50%, and only one (4.3%) JAK2-positive patient 
had a platelet RNA allele burden 25%.
Treatment response
At 12 months in the safety analysis set, the median (range) 
platelet count was 416.6×109/L (235–854) in the JAK2-positive 
group and 425.0×109/L (165–1,279) in the JAK2-negative 
group. At 12 months, 35 patients (14 patients in the JAK2-
positive group and 21 patients in the JAK2-negative group) 
had an available platelet sample for evaluation. Of these 
35 patients, 26 (74.3%) achieved at least a partial platelet 
response (600×109/L) (95% CI 57.9, 85.8). The propor-
tion of patients who achieved at least a partial response was 
higher in the JAK2-positive group (n=12 [85.7%]; 95% CI 
60.1, 96.0) than in the JAK2-negative group (n=14 [66.7%]; 
95% CI 45.4, 82.8). The odds of patients in the JAK2-positive 
group achieving at least a partial platelet response were 3.00 
times higher than in the JAK2-negative group, although this 
difference was not statistically significant (95% CI 0.44, 
33.97) (Figure 1A).
By using the LOCF approach in the sensitivity analysis, 
33 (71.7%) patients achieved at least a partial response 
(95% CI 57.5, 82.7). The response rate in the JAK2-positive 
group was more similar to the JAK2-negative group than in 
the main analysis. The proportion of patients with at least a 
partial response was higher in the JAK2-positive group (n=17 
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Table 1 Patient demographics and baseline characteristics (safety set)
Characteristic JAK2-positive (N=23) JAK2-negative (N=24) Total (N=47)
age, years
Mean (sD) 57.4 (14.00) 58.6 (15.94) 58.0 (14.87)
Median (range) 59.0 (36–85) 60.5 (27–89) 60.0 (27–89)
sex, n (%)
Male 9 (39.1) 10 (41.7) 19 (40.4)
Female 14 (60.9) 14 (58.3) 28 (59.6)
JAK2 mutation status, n (%)
Positive 23 (100.0) 0 23 (48.9)
negative 0 24 (100.0) 24 (51.1)
allele burden: granulocyte Dna, %a n=22
Mean (sD) 35.5 (16.17) n/a n/a
Median 30.5 n/a n/a
Q1, Q3 21.0, 44.0 n/a n/a
range 17–72 n/a n/a
allele burden: platelet rna, %a n=22
Mean (sD) 39.0 (11.91) n/a n/a
Median 35.0 n/a n/a
Q1, Q3 30.0, 47.0 n/a n/a
range 24–68 n/a n/a
hematological parameters, median (range)
Platelet count, ×109/l 584.0 (310–1,158) 752.5 (323–2,126) 646.0 (310–2,126)
hematocrit, fraction of 1 0.419 (0.30–0.50) 0.370 (0.29–0.46) 0.387 (0.29–0.50)
hemoglobin, g/l 137.0 (97–157) 122.0 (84–158) 130.0 (84–158)
White blood cells, ×109/l 7.70 (4.1–18.1) 6.81 (3.6–15.2) 7.03 (3.6–18.1)
Prior cytoreductive therapy, n (%)b 22 (95.7) 19 (79.2) 41 (87.2)
Busulfan 1 (4.3) 0 1 (2.1)
hydroxycarbamide 21 (91.3) 18 (75.0) 39 (83.0)
interferonc 3 (13.07) 4 (16.7) 7 (14.9)
Pipobroman 0 1 (4.2) 1 (2.1)
Notes: aBaseline is the first reported allele burden value available in the study. bPercentages are based on all patients in the safety set for each JAK2 status group. Medications 
were coded using the World health Organization’s Drug Dictionary version 2013seP01. Patients were counted once per category per treatment group. Prior medications 
include all medications received by the patient in the 30 days prior to the commencement of anagrelide. cincludes interferon, interferon alfa, interferon alfa-n1, and 
peginterferon alfa-2a.
Abbreviations: n/a, not applicable; Q, quartile; sD, standard deviation.
Figure 1 Treatment response comparisons at 12 months for the JAK2-positive and JAK2-negative groups.
Notes: (A) Full analysis set; (B) lOcF sensitivity analyses.
Abbreviations: CI, confidence interval; LOCF, last observation carried forward; OR, odds ratio.
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[77.3%]; 95% CI 56.6, 89.9) than in the JAK2-negative group 
(n=16 [66.7%]; 95% CI 46.7, 82.0). The odds of patients in 
the JAK2-positive group achieving at least a partial response 
in the LOCF sensitivity analysis were 1.7 times higher than in 
the JAK2-negative group (Figure 1B). However, this differ-
ence was not statistically significant (95% CI 0.39, 8.02).
At 12 months, 15 patients (42.9%) had achieved a 
complete platelet response (400×109/L) (95% CI 28.0, 
59.1). A higher proportion of JAK2-positive patients (n=7 
[50.0%]; 95% CI 26.8, 73.2) achieved a complete platelet 
response than JAK2-negative patients (n=8 [38.1%]; 95% 
CI 20.8, 59.1). The odds of patients in the JAK2-positive 
group achieving a complete platelet response were 1.63 
times higher than in the JAK2-negative group, although this 
difference was not statistically significant (95% CI 0.34, 
7.86) (Figure 1A).
In the sensitivity analysis using the LOCF approach, 16 
(34.8%) patients achieved a complete platelet response at 
12 months (95% CI 0.29, 4.56). The proportion of patients 
who achieved a complete response was higher in the JAK2-
positive group (n=8 [36.4%]; 95% CI 19.7, 57.0) than in the 
JAK2-negative group (n=8 [33.3%]; 95% CI 18.0, 53.3). 
The odds of patients in the JAK2-positive group achieving a 
complete platelet response in the LOCF sensitivity analysis 
were 1.14 times higher than in the JAK2-negative group, 
although this difference was not statistically significant (95% CI 
0.29, 4.56) (Figure 1B).
Platelet responses to anagrelide treatment were also 
observed at 6 months, although the difference in platelet 
responses between the JAK2-positive and JAK2-negative 
groups at this time was not as pronounced as that observed 
at 12 months (Figure 2).
allele burden
In JAK2-positive patients, no clear relationship was identi-
fied between platelet response and baseline allele burden. 
The median allele burden for the 12 patients who achieved 
at least a partial response at 12 months and had a suitable 
platelet sample was 41.0% (range: 17–47) for granulocyte 
DNA and 49.5% (range: 31–58) for platelet RNA. There was 
no clinically relevant change in allele burden from baseline 
over the 12 months of treatment with anagrelide (data not 
shown).
exposure and safety
The mean (standard deviation) daily dose of anagrelide 
was 1.40 (0.482) mg/day overall, 1.32 (0.378) mg/day in 
the JAK2-positive group, and 1.47 (0.563) mg/day in the 
JAK2-negative group. Total exposure was similar in JAK2-
positive (19.6 person-years) and JAK2-negative patients 
(22.8 person-years).
A total of 15 (31.9%) patients experienced 20 ADRs 
(Table 2). Fewer patients in the JAK2-positive group had 
an ADR than in the JAK2-negative group (26.1% versus 
37.5%). The most common ADR was headache (12.8%). 
All of the ADRs reported were of mild or moderate sever-
ity. None of the ADRs were fatal, serious, or severe and no 
deaths occurred during the study. Three patients were with-
drawn due to an ADR (dermatitis and pruritus in the JAK2-
positive group and headache in the JAK2-negative group). 
Figure 2 Treatment response comparisons at 6 months for the JAK2-positive and JAK2-negative groups.
Notes: (A) Full analysis set; (B) lOcF sensitivity analyses.
Abbreviations: CI, confidence interval; LOCF, last observation carried forward; OR, odds ratio.
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There were no notable changes from baseline to 12 months 
in any hematological parameters other than platelets.
Discussion
In this hypothesis-generating study, the overall platelet response 
rate to anagrelide in patients with ET was found to be high irre-
spective of JAK2 mutation status. Our findings are in line with 
the efficacy of anagrelide observed in other studies in patients 
with ET.22,24–26 Previous studies have shown that responses 
to anagrelide are unaffected by JAK2 mutation status.27,29 
In the current study, we found the likelihood of having at least 
a partial response to anagrelide to be higher in JAK2-positive 
patients than in those who were JAK2-negative. However, the 
sensitivity analyses using LOCF showed more comparable 
treatment response findings between the JAK2-positive and 
JAK2-negative groups and lower ORs, indicating a similar sen-
sitivity to anagrelide independent of JAK2 mutation status.
No clear relationship or clinically relevant difference was 
identified between JAK2 allele burden and platelet treatment 
response in this study, and there was no significant change 
in allele burden over the 12 months of anagrelide therapy. 
The majority of JAK2-positive patients had an allele burden 
of 25%–50%, regardless of whether this was measured 
using granulocyte DNA or platelet RNA methodology. JAK2 
allele burden appears to play a role in clinical phenotype and 
disease evolution in ET.9,13
Anagrelide was found to be well tolerated in this study, 
with a safety profile consistent with the SPC22 and current 
Table 2 adverse drug reactions (safety set)
Category, n (%) JAK2-positive  
(N=23)
JAK2-negative  
(N=24)
Total  
(N=47)
any aDr 6 (26.1) 9 (37.5) 15 (31.9)
severe aDrs 0 0 0
saDrs 0 0 0
aDr causing withdrawal  
of anagrelide
2 (8.7)a 1 (4.2)b 3 (6.4)
Deaths 0 0 0
aDrs by preferred term
headache 2 (8.7) 4 (16.7) 6 (12.8)
anemia 1 (4.3) 2 (8.3) 3 (6.4)
Palpitations 1 (4.3) 1 (4.2) 2 (4.3)
Tachycardia 1 (4.3) 1 (4.2) 2 (4.3)
scotoma 0 1 (4.2) 1 (2.1)
Diarrhea 0 1 (4.2) 1 (2.1)
hyperuricemia 0 1 (4.2) 1 (2.1)
Presyncope 1 (4.3) 0 1 (2.1)
Dermatitis 1 (4.3) 0 1 (2.1)
Pruritus 0 1 (4.2) 1 (2.1) 
Notes: aheadache, n=1; dermatitis, n=1; bPruritus.
Abbreviations: aDr, adverse drug reaction; saDr, serious adverse drug reaction.
literature.26,30,31 The frequency of ADRs was lower than that 
reported in the current literature, but there is no obvious 
explanation for this finding. The most commonly reported 
ADR was headache. All of the ADRs reported were of mild or 
moderate severity, no severe or serious ADRs occurred, and 
few patients were withdrawn due to an ADR. Three patients 
were withdrawn due to transformation to myelofibrosis, but 
these cases were not considered to be related to anagrelide 
because of the short time interval between anagrelide initia-
tion and myelofibrosis diagnosis. No thrombotic or hemor-
rhagic complications were reported over the duration of this 
study. Furthermore, no differences in ADRs were evident 
between the JAK2-positive and JAK2-negative groups.
It should be noted that results from this study were not 
statistically significant (CIs were wide) and data should be 
interpreted with caution due to the small study size. In addi-
tion, the imbalance of patients who remained in the study at 
12 months between groups could have added potential bias 
to the results. This is supported by the sensitivity analyses 
using LOCF, which showed more comparable treatment 
response findings between the two groups.
Conclusion
In conclusion, the overall platelet response rate was high in 
both JAK2-positive and JAK2-negative patients with ET in 
this study. The odds of achieving at least a partial response 
were found to be slightly higher if patients had a JAK2(V617F) 
mutation than if they did not. However, no firm conclusions can 
be made and a larger well-controlled study would be needed to 
confirm the findings of this hypothesis-generating study.
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